Summary

Your CYP1A2 result determines how fast your liver clears caffeine — fast metabolisers (AA) can drink coffee with minimal cardiovascular risk, while slow metabolisers (CC) keep caffeine circulating 2-3x longer, increasing heart attack risk with high intake and disrupting sleep even from afternoon coffee.

Genotype spectrum

AA (Fast metaboliser)

Coffee is genuinely protective for you. Multiple large studies show 2-3 cups/day is associated with REDUCED cardiovascular risk in fast metabolisers.

AC (Intermediate metaboliser)

Moderate caffeine intake is well-tolerated. You sit in the middle — cardiovascular risk from coffee is neutral to slightly positive at moderate intake (1-2 cups/day).

CC (Slow metaboliser)

You extract maximum effect from minimum caffeine. One cup does what three do for a fast metaboliser.

Practical takeaway

For CC Carriers (Slow Metaboliser — Priority Tier)

Caffeine management:
• Limit to 1-2 cups of coffee per day (100-200mg caffeine). This is your moderate zone where cardiovascular risk remains neutral.
• Morning only. Your last caffeine should be before 10am if sleep onset is around 10-11pm. That gives ~12 hours of clearance. This sounds extreme but matches your pharmacokinetics.
• Tea is your friend. Lower caffeine per cup (40-70mg vs 80-120mg for coffee), plus L-theanine provides a smoother experience. Green tea specifically.
• Pre-workout caffeine: If you use caffeine for exercise performance, keep the dose LOW (1-2mg/kg rather than the standard 3-6mg/kg research dose). The Guest et al. study showed caffeine IMPAIRED cycling performance in slow metabolisers at standard doses.

What to track:
• Sleep onset latency (how long to fall asleep) — if this increases, your caffeine cutoff is too late
• Resting heart rate (trend over weeks, not daily fluctuation)
• Blood pressure if other cardiovascular risk factors are present

What "working" looks like:
• Consistent sleep onset without caffeine interference
• Stable resting heart rate
• Enjoying caffeine's cognitive benefits without the cardiovascular downside
• No afternoon energy crashes (these often come from caffeine wearing off too slowly and disrupting prior night's sleep)

Expected response window: Immediate. Adjusting caffeine intake produces noticeable changes in sleep quality within 3-7 days. Blood pressure effects resolve within 2-4 weeks of reducing intake.
For AC Carriers (Intermediate — Moderate Adjustment)
• 2-3 cups of coffee daily is your moderate zone
• Set a personal caffeine cutoff — start with 2pm, adjust based on sleep quality
• If you also carry slow COMT (Met/Met), treat your effective clearance as closer to CC — the catecholamine effects persist even after caffeine itself is partially cleared
• Standard pre-workout caffeine doses (3mg/kg) likely effective but monitor response
For AA Carriers (Fast Metaboliser — Lean Into Your Advantage)
• Coffee is genuinely protective for you at moderate intake (2-3 cups/day). Enjoy it.
• You can use caffeine as a reliable exercise performance tool at stand

Evidence detail

What This Gene Does

CYP1A2 is the liver enzyme responsible for ~95% of caffeine metabolism. It breaks caffeine down into its metabolites (paraxanthine, theobromine, theophylline), determining how long caffeine stays active in your bloodstream. The rs762551 variant controls how much CYP1A2 enzyme your liver produces — the A allele drives higher expression (more enzyme, faster clearance), while the C allele means lower expression (less enzyme, slower clearance).

This isn't about caffeine sensitivity in terms of how it feels — that's more ADORA2A. This is about pharmacokinetics: how long caffeine physically remains in your system, affecting your cardiovascular system, sleep architecture, and interaction window with other substances.

Mechanism

CYP1A2 is a phase I metabolic enzyme in the liver. Here's what happens when you drink coffee:

1. Caffeine is absorbed from the gut into the bloodstream (peak plasma levels ~30-60 minutes).
2. Caffeine reaches the liver, where CYP1A2 performs N-demethylation — removing methyl groups from caffeine's three nitrogen atoms.
3. Primary metabolite: Paraxanthine (~80% of caffeine metabolism). Also theobromine (~10%) and theophylline (~5%).
4. Further metabolism breaks these down into uric acid derivatives for excretion.

The AA vs CC difference:

The A allele at rs762551 creates a higher-expression version of the CYP1A2 gene. AA homozygotes produce more CYP1A2 enzyme, clearing caffeine faster. This is why:
• AA (fast): Caffeine half-life ~3-4 hours. A morning coffee is largely cleared by afternoon. The cardiovascular system has less cumulative caffeine exposure.
• CC (slow): Caffeine half-life ~8-12 hours. A morning coffee is still significantly present at bedtime. Each cup adds to a higher steady-state caffeine level. The cardiovascular system is chronically exposed.

Why slow metabolisers face cardiovascular risk:

Caffeine acutely raises blood pressure (by ~5-10 mmHg systolic), increases heart rate, and stimulates catecholamine release. In fast metabolisers, this is transient — the spike resolves as caffeine is cleared. In slow metabolisers, the effect is prolonged. Multiple daily cups create sustained haemodynamic stress. Over years, this chronic low-grade cardiovascular load accumulates into measurable risk.

Why fast metabolisers are PROTECTED:

Coffee contains ~1000 bioactive compounds beyond caffeine — chlorogenic acids, polyphenols, diterpenes, melanoidins. These have anti-inflammatory, antioxidant, and cardioprotective effects. In fast metabolisers, the caffeine-mediated harm resolves quickly, while the protective compounds persist. Net effect: positive. In slow metabolisers, the caffeine harm persists alongside the benefits, tipping the balance negative at high intake.

CYP1A2 Caffeine

Summary

Genotype spectrum

Practical takeaway

Evidence detail

Sources (10)